TLSI
TriSalus Life Sciences, Inc.
NasdaqGM Healthcare United States
4,38 $US
+1.39% today
-28.20% YTD · -5.40% 1Y
0
Insider transactions
SEC Form 4 · AMF · BaFin — rolling 90 days
15
Hedge funds tracked
Latest available SEC 13F filings
60
/ 100
STRONG

Analysis TriSalus Life Sciences, Inc. (TLSI) — Kairos Score 60/100

Composite score aggregating 8 smart money dimensions: insiders (SEC/AMF/BaFin), hedge funds, politicians & gurus, price momentum, valuation, analyst consensus, financial health, earnings momentum. The higher the score, the more favorable the institutional signals consensus.

💡 Detailed breakdown (the 8 sub-scores) available in the Premium dashboard.

About TriSalus Life Sciences, Inc.

TriSalus Life Sciences, Inc. engages in the research, development, and commercialization of drug delivery technology platform and immuno-oncology therapeutics to improve outcomes for patients with difficult-to-treat liver and pancreatic cancers in the United States. It offers Pressure-Enabled Drug Delivery (PEDD) infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial for treating locally advanced pancreatic cancer. The company is also developing nelitolimod, an investigational immunotherapeutic in Phase 1 clinical trial for the treatment of uveal melanoma, intrahepatic cholangiocarcinoma, hepatocellular carcinoma, and pancreatic cancer. It serves interventional radiologists, IR technicians, medical oncologists, nursing support, and value analysis committee staff. The company was founded in 2009 and is headquartered in Westminster, Colorado.

Key info

👔
CEO
Ms. Mary T. Szela B.S.N., M.B.A.
📍
HQ
6272 West 91st Avenue, Westminster, CO, 80031, United States
👥
Employees
102
💰
Market cap
266 002 300,00 $US
💸
Dividend yield
—

🕴️ Insider activity (90 days)

0 transactions — 0 buys and 0 sales reported by TriSalus Life Sciences, Inc. executives.

🏦 Hedge Funds

15 institutional funds report a position on TLSI in their latest SEC quarterly filing.

BlackRock, Inc.
VANGUARD GROUP INC
VANGUARD CAPITAL MANAGEMENT LLC
Cerity Partners LLC
GEODE CAPITAL MANAGEMENT, LLC

📰 Recent news

15 recent articles on TLSI.

🧠 What makes Kairos Insider

Beyond raw data, we aggregate and score every smart money signal to give you a unique view.

🧠

Kairos Score 0-100

8-dimension composite score: insiders · hedge funds · politicians · momentum · valuation · health · analysts · earnings.

🎯

Insider Clusters

Detection of clustered purchases or sales by several executives in the same stock.

🏦

13F Hedge Funds

Berkshire, Pershing Square, Tiger Global, Bridgewater and other reporting funds.

📈

ETF Rotations

NANC & GOP (Pelosi & Republicans), GURU (top hedge funds), ARK (Cathie Wood). See who enters and exits each week.

🔥

Google Trends

Spot marked changes in search interest around the stocks being followed.

📧

Email alerts

Create your watchlist and receive a brief of events affecting your tickers.

Companies in the same sector as TriSalus Life Sciences, Inc.

Official sources · Public data · SEC EDGAR — Form 4 & 13F · AMF — Executive filings · BaFin — Directors' Dealings · Yahoo Finance · Alpha Vantage

🔓 Unlock the full analysis

This public page only shows a preview. The full analysis of TLSI on the Kairos Insider dashboard includes:

✅ Full Kairos Score (8-axis radar + synthesis)
✅ History of all 0 insider transactions over 90 days
✅ All 15 detected institutional funds
✅ Thematic ETFs (ARK, BUZZ, NANC, GOP, JEPI…)
✅ Hot Stocks Google Trends
✅ Available history: AUM + rotations
✅ Fundamentals (P/E, PEG, EV/EBITDA, ROE…)
✅ Financial health (Altman Z, Piotroski F)
✅ Sector peers + recent earnings
See full analysis →
Analyze other tickers for free →

Free signup · Pro €19/month or €190/year